Tianyin Pharmaceutical Co., Inc. Provides Fiscal 201...(or the year. Netincome forecasted does n...),Health

Date:6/18/2009

or the year. Net income forecasted does not include non-cash expenses associated with stock compensation plans or future interest expense. This guidance does not include any contribution from potential future acquisitions and management will continue to evaluate its business outlook as necessary and communicate any changes on a quarterly basis or when appropriate. At the time of this release, the Company does not have any formal agreements nor is it involved in any definitive discussions regarding potential acquisitions.

Growth will be supported by a number of initiatives, including: 1) Receiving GMP certification for Tianyin's new production facility will increase its capacity for solid dosage by 300% and enable future growth for 20 of its products; 2) this new facility will enable the company to initiate a wholesale component to its business focused exclusively on distributing higher margin, specialty products for other pharmaceutical manufactures through the existing sales force and distribution channels; 3) the new Healthcare Reform Act is expected to increase the demand for approximately 20 of the total 22 drugs Tianyin currently has listed in the reimbursement catalog; 4) expanding its targeted marketing strategy, including multi-media and television advertising, to further brand and promote higher gross-profit-margin products, such as Ginkgo Mihuan Oral Liquid and Xuelian Cangcao; 5) expand collaboration with universities and research organizations to complement Tianyin's internal drug development efforts and continue introducing new products to the market; and, 6) continue looking for complementary acquisitions primarily focused on existing product lines which would increase the depth and breadth of the existing portfolio.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired b
'/>"/>

SOURCE Tianyin Pharmaceutical, Co., Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker OTC BB: TYNP
2. Tianyin Pharmaceutical to Present at Roth Third Annual China Discovery Tour in Beijing on May 20, 2008 at 12:40 p.m. Beijing Time
3. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
4. Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results
5. Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors
6. Tianyin Pharmaceutical Co., Inc. Completes Production for Earthquake
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
8. Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction
9. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets
10. Tianyin Pharmaceutical Co., Inc. Authorizes $3.0 Million Stock Repurchase Program
11. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST